@article{23b71c9e879140f8b7831d44652e68a7,
title = "Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer",
abstract = "Liquid biopsy applications derived from circulating tumor cells, circulating tumor DNA, and extracellular vesicles in prostate cancer have been proved to be useful for monitoring tumor genomic evolution, disease progression, and response to therapy. Although further clinical qualification is needed, liquid biopsies can contribute toward implementation of precision care.",
keywords = "Circulating tumor cell, Circulating tumor DNA, Extracellular vesicles, Genomics, Liquid biopsy, Precision medicine, Prostate cancer",
author = "Irene Casanova-Salas and Alejandro Athie and Boutros, {Paul C.} and {Del Re}, Marzia and Miyamoto, {David T.} and Pienta, {Kenneth J.} and Posadas, {Edwin M.} and Sowalsky, {Adam G.} and Arnulf Stenzl and Wyatt, {Alexander W.} and Joaquin Mateo",
note = "Funding Information: Financial disclosures: Joaquin Mateo certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: P.C. Boutros is a member of the Scientific Advisory Boards of BioSymetrics Inc. and Intersect Diagnostics Inc. M. Del Re is a consultant for Ipsen, Janssen, Sanofi-Aventis, and Novartis. K.J. Pienta is a consultant for Cue Biopharma, Inc.; is a founder of Keystone Biopharma, Inc.; and receives research support from Progenics, Inc. J. Mateo has served on scientific advisory boards from Amgen, AstraZeneca, Clovis Oncology, Janssen, Merck/MSD, and Roche; has participated in speaker bureaus from AstraZeneca, Pfizer, Janssen, Sanofi, and Astellas Pharma; and has received research funding from AstraZeneca and Pfizer Oncology through grants to the institution. The remaining authors have nothing to disclose. Funding Information: Funding/Support and role of the sponsor: Irene Casanova-Salas was supported by a PERIS fellowship from the Departament de Salut Generalitat de Catalunya ( SLT008/18/00185 ), and by a fellowship from “la Caixa” Foundation ( ID 100010434 ) and from the European Union{\textquoteright}s Horizon 2020 research and innovation program under the Marie Sk{\l}odowska-Curie grant agreement number 847648 . The fellowship code is LCF/BQ/PI20/11760033. This work was supported in part by the Intramural Research Program of the National Cancer Institute, NIH ; by the NIH/NCI under award number P30CA016042 ; and through an operating grant from the Early Detection Research Network ( 1U01CA214194-01 ) to Paul C. Boutros. The authors affiliated to VHIO (Irene Casanova-Salas, Alejandro Athie, and Joaquin Mateo) acknowledge funding from the Cellex Foundation , and “la Caixa” Foundation (LCF/PR17/51120011)), AECC (Spanish Association Against Cancer) Scientific Foundation , and Fundacion FERO . Joaquin Mateo acknowledges support from the Instituto de Salud Carlos III (grant PI18/01384 ) and Prostate Cancer Foundation Young Investigator program .",
year = "2021",
doi = "10.1016/j.eururo.2020.12.037",
language = "English (US)",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
}